Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.

metastasis nivolumab oral cancer prognostic factor recurrence retrospective

Journal

Oral diseases

ISSN: 1601-0825

Titre abrégé: Oral Dis

Pays: Denmark

ID NLM: 9508565

Informations de publication

Date de publication:
15 Dec 2022

Historique:

revised: 03 12 2022

received: 13 09 2022

accepted: 11 12 2022

pubmed: 16 12 2022

medline: 16 12 2022

entrez: 15 12 2022

Statut: aheadofprint

Résumé

Immunotherapy with nivolumab for patients with recurrent/metastatic oral squamous cell carcinoma has not been evaluated. Here, we aimed to examine the efficacy, safety, and prognostic factors of nivolumab in these patients. This multicenter retrospective observational study involved patients who received nivolumab between April 2017 and June 2019. The patient characteristics were evaluated for association with progression-free and overall survival. Progression-free and overall survival rates were calculated; parameters that were significant in the univariate analysis were used as explanatory variables. Independent factors for progression-free and overall survival were identified using multivariate analysis. Totally, 143 patients were included. The overall response and disease control rates were 27.3% and 46.2%, respectively. The median, 1- and 2-year progression-free survival rates were 2.7 months, 25.4%, and 19.2%, respectively; those for overall survival were 11.2 months, 47.3%, and 33.6%, respectively. The independent factors affecting progression-free survival were performance status and immune-related adverse event occurrence, whereas those affecting overall survival were performance status, target disease, and number of previous lines of systemic cancer therapy. Eight patients reported grade ≥3 immune-related adverse events. Nivolumab was effective for recurrent/metastatic oral squamous cell carcinoma treatment and was well tolerated by patients.

Identifiants

DOI: 10.1111/odi.14471 PMID: 36519515

pubmed: 36519515

doi: 10.1111/odi.14471

doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Références

Adachi, Y., Tamiya, A., Taniguchi, Y., Enomoto, T., Azuma, K., Kouno, S., Inagaki, Y., Saijo, N., Okishio, K., & Atagi, S. (2020). Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Cancer Medicine, 9, 1383-1391. https://doi.org/10.1002/cam4.2807

Bernier, J., Cooper, J. S., Pajak, T. F., van Glabbeke, M., Bourhis, J., Forastiere, A., Ozsahin, E. M., Jacobs, J. R., Jassem, J., Ang, K. K., & Lefèbvre, J. L. (2005). Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head and Neck, 27, 843-850. https://doi.org/10.1002/hed.20279

Bernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefèbvre, J. L., Greiner, R. H., Giralt, J., Maingon, P., Rolland, F., Bolla, M., Cognetti, F., Bourhis, J., Kirkpatrick, A., van Glabbeke, M., & European Organization for Research and Treatment of Cancer Trial 22931. (2004). Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New England Journal of Medicine, 350, 1945-1952. https://doi.org/10.1056/NEJMoa032641

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492

Cohen, E. E. W., Soulières, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M. J., Soria, A., Machiels, J. P., Mach, N., Mehra, R., Burtness, B., Zhang, P., Cheng, J., Swaby, R. F., Harrington, K. J., & KEYNOTE-040 Investigators. (2019). Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet, 393, 156-167. https://doi.org/10.1016/S0140-6736(18)31999-8

Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., Machtay, M., Ensley, J. F., Chao, K. S., Schultz, C. J., Lee, N., Fu, K. K., & Radiation Therapy Oncology Group 9501/Intergroup. (2004). Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 350, 1937-1944. https://doi.org/10.1056/NEJMoa032646

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45, 228-247. https://doi.org/10.1016/j.ejca.2008.10.026

Ferris, R. L., Blumenschein, G., Jr., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., … Gillison, M. L. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 375, 1856-1867. https://doi.org/10.1056/NEJMoa1602252

Ferris, R. L., Blumenschein, G., Jr., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, L. C. I., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Lynch, M., Jayaprakash, V., … Gillison, M. L. (2018). Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncology, 81, 45-51. https://doi.org/10.1016/j.oraloncology.2018.04.008

Fushimi, C., Okamoto, I., Matsuki, T., Masubuchi, T., Okada, T., Sato, H., Tsukahara, K., Kondo, T., Yamashita, T., Hanyu, K., Omura, G. O., Takahashi, H., Tada, Y., & Miura, K. (2020). Salvage chemotherapy after nivolumab for recurrent or metastatic head and neck carcinoma. Anticancer Research, 40, 5277-5283. https://doi.org/10.21873/anticanres.14532

Hanai, N., Shimizu, Y., Kariya, S., Yasumatsu, R., Yokota, T., Fujii, T., Tsukahara, K., Yoshida, M., Hanyu, K., Ueda, T., Hirakawa, H., Takahashi, S., Ono, T., Sano, D., Yamauchi, M., Watanabe, A., Omori, K., Yamazaki, T., Monden, N., … Homma, A. (2021). Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: A multicenter retrospective clinical study. International Journal of Clinical Oncology, 26, 494-506. https://doi.org/10.1007/s10147-020-01829-0

Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., & Nakagawa, K. (2018). Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncology, 4, 374-378. https://doi.org/10.1001/jamaoncol.2017.2925

Ho, W. J., Yarchoan, M., Hopkins, A., Mehra, R., Grossman, S., & Kang, H. (2018). Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. Journal for Immunotherapy of Cancer, 6, 84. https://doi.org/10.1186/s40425-018-0395-x

Hori, R., Shinohara, S., Kojima, T., Kagoshima, H., Kitamura, M., Tateya, I., Tamaki, H., Kumabe, Y., Asato, R., Harada, H., Kitani, Y., Tsujimura, T., Honda, K., Ichimaru, K., & Omori, K. (2019). Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma. Cancers, 11, 1317. https://doi.org/10.3390/cancers11091317

Inoue, H., Yokota, T., Hamauchi, S., Onozawa, Y., Kawakami, T., Shirasu, H., Notsu, A., Yasui, H., & Onitsuka, T. (2020). Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. Auris Nasus Larynx, 47, 650-657. https://doi.org/10.1016/j.anl.2020.01.003

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Kang, S. P., … Gangadhar, T. C. (2018). Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clinical Cancer Research, 24, 4960-4967. https://doi.org/10.1158/1078-0432.CCR-17-2386

Judd, J., Zibelman, M., Handorf, E., O'Neill, J., Ramamurthy, C., Bentota, S., Doyle, J., Uzzo, R. G., Bauman, J., Borghaei, H., Plimack, E. R., Mehra, R., & Geynisman, D. M. (2017). Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors. The Oncologist, 22, 1232-1237. https://doi.org/10.1634/theoncologist.2017-0133

Kacew, A. J., Harris, E. J., Lorch, J. H., Schoenfeld, J. D., Margalit, D. N., Kass, J. I., Tishler, R. B., Haddad, R. I., & Hanna, G. J. (2020). Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 105, 104676. https://doi.org/10.1016/j.oraloncology.2020.104676

Kurosaki, T., Mitani, S., Tanaka, K., Suzuki, S., Kanemura, H., Haratani, K., Fumita, S., Iwasa, T., Hayashi, H., Yoshida, T., Ishikawa, K., Kitano, M., Otsuki, N., Nishimura, Y., Doi, K., & Nakagawa, K. (2021). Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: A single-center retrospective study. Anti-Cancer Drugs, 32, 95-101. https://doi.org/10.1097/CAD.0000000000001006

Kwon, M., Kim, R. B., Roh, J. L., Lee, S. W., Kim, S. B., Choi, S. H., Nam, S. Y., & Kim, S. Y. (2017). Prevalence and clinical significance of cancer cachexia based on time from treatment in advanced-stage head and neck squamous cell carcinoma. Head and Neck, 39, 716-723. https://doi.org/10.1002/hed.24672

Lala, M., Chirovsky, D., Cheng, J. D., & Mayawala, K. (2018). Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review. Oral Oncology, 84, 108-120. https://doi.org/10.1016/j.oraloncology.2018.07.005

Lang, D., Huemer, F., Rinnerthaler, G., Horner, A., Wass, R., Brehm, E., Akbari, K., Granitz, M., Hutarew, G., Kaiser, B., Greil, R., & Lamprecht, B. (2019). Therapy line and associated predictors of response to PD-1/PD-L1-inhibitor monotherapy in advanced non-small-cell lung cancer: A retrospective bi-centric cohort study. Targeted Oncology, 14, 707-717. https://doi.org/10.1007/s11523-019-00679-9

Matsuki, T., Okamoto, I., Fushimi, C., Sawabe, M., Kawakita, D., Sato, H., Tsukahara, K., Kondo, T., Okada, T., Tada, Y., Miura, K., Omura, G., & Yamashita, T. (2020). Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Medicine, 9, 5015-5024. https://doi.org/10.1002/cam4.3124

Matsuki, T., Okamoto, I., Fushimi, C., Takahashi, H., Okada, T., Kondo, T., Sato, H., Ito, T., Tokashiki, K., Tsukahara, K., Hanyu, K., Masubuchi, T., Tada, Y., Miura, K., Omura, G., Sawabe, M., Kawakita, D., & Yamashita, T. (2020). Real-world, long-term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best overall response: A retrospective multicenter study of 88 patients. Cancers, 12, 3427. https://doi.org/10.3390/cancers12113427

McMillan, D. C., Crozier, J. E., Canna, K., Angerson, W. J., & McArdle, C. S. (2007). Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. International Journal of Colorectal Disease, 22, 881-886. https://doi.org/10.1007/s00384-006-0259-6

Morita, R., Okishio, K., Shimizu, J., Saito, H., Sakai, H., Kim, Y. H., Hataji, O., Yomota, M., Nishio, M., Aoe, K., Kanai, O., Kumagai, T., Kibata, K., Tsukamoto, H., Oizumi, S., Fujimoto, D., Tanaka, H., Mizuno, K., Masuda, T., … Ohe, Y. (2020). Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer, 140, 8-18. https://doi.org/10.1016/j.lungcan.2019.11.014

Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., Abe, T., Funakoshi, T., Yamamoto, N., Amagai, M., & Yamazaki, N. (2016). Nivolumab for advanced melanoma: Pretreatment prognostic factors and early outcome markers during therapy. Oncotarget, 7, 77404-77415. https://doi.org/10.18632/oncotarget.12677

Nishikawa, D., Suzuki, H., Koide, Y., Beppu, S., Kadowaki, S., Sone, M., & Hanai, N. (2018). Prognostic markers in head and neck cancer patients treated with nivolumab. Cancers, 10, 466. https://doi.org/10.3390/cancers10120466

Park, S. E., Lee, S. H., Ahn, J. S., Ahn, M. J., Park, K., & Sun, J. M. (2018). Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 106-111. https://doi.org/10.1016/j.jtho.2017.10.011

Pestana, R. C., Becnel, M., Rubin, M. L., Torman, D., Crespo, J., Phan, J., Hanna, E., Bell, D., Glisson, B. S., Johnson, J. M., Lee, J. J., & Ferrarotto, R. (2020). Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 101, 104523. https://doi.org/10.1016/j.oraloncology.2019.104523

Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., Adrados, M., Costas, P., Aspa, J., Alfranca, A., Mondéjar, R., & Colomer, R. (2019). Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. European Journal of Cancer, 109, 21-27. https://doi.org/10.1016/j.ejca.2018.10.014

Rossi, C., Gilhodes, J., Maerevoet, M., Herbaux, C., Morschhauser, F., Brice, P., Garciaz, S., Borel, C., Ysebaert, L., Obéric, L., Lazarovici, J., Deau, B., Dupuis, J., Chauchet, A., Abraham, J., Bijou, F., Stamatoullas-Bastard, A., Malfuson, J. V., Golfier, C., … Ghesquières, H. (2018). Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. American Journal of Hematology, 93, 1042-1049. https://doi.org/10.1002/ajh.25154

Saleh, K., Daste, A., Martin, N., Pons-Tostivint, E., Auperin, A., Herrera-Gomez, R. G., Baste-Rotllan, N., Bidault, F., Guigay, J., Le Tourneau, C., Saada-Bouzid, E., & Even, C. (2019). Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer, 121, 123-129. https://doi.org/10.1016/j.ejca.2019.08.026

Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., Nakanishi, M., & Yamamoto, N. (2018). Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer, 115, 71-74. https://doi.org/10.1016/j.lungcan.2017.11.019

Schvartsman, G., Peng, S. A., Bis, G., Lee, J. J., Benveniste, M. F. K., Zhang, J., Roarty, E. B., Lacerda, L., Swisher, S., Heymach, J. V., Fossella, F. V., & William, W. N. (2017). Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 112, 90-95. https://doi.org/10.1016/j.lungcan.2017.07.034

Specenier, P. M., & Vermorken, J. B. (2008). Recurrent head and neck cancer: Current treatment and future prospects. Expert Review of Anticancer Therapy, 8, 375-391. https://doi.org/10.1586/14737140.8.3.375

Szabados, B., van Dijk, N., Tang, Y. Z., van der Heijden, M. S., Wimalasingham, A., Gomez de Liano, A., Chowdhury, S., Hughes, S., Rudman, S., Linch, M., & Powles, T. (2018). Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. European Urology, 73, 149-152. https://doi.org/10.1016/j.eururo.2017.08.022

Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G., Garon, E. B., Riess, J. W., Jain, L., Mayawala, K., Kang, J., Ebbinghaus, S. W., Sinha, V., de Alwis, D. P., & Stone, J. A. (2018). Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clinical Cancer Research, 24, 5841-5849. https://doi.org/10.1158/1078-0432.CCR-18-0415

Uehara, Y., Hakozaki, T., Kitadai, R., Narita, K., Watanabe, K., Hashimoto, K., Kawai, S., Yomota, M., & Hosomi, Y. (2022). Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy. Translational Lung Cancer Research, 11, 135-149. https://doi.org/10.21037/tlcr-21-815

Ueki, Y., Takahashi, T., Ota, H., Shodo, R., Yamazaki, K., & Horii, A. (2020). Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: Prognostic value of combined performance status and modified Glasgow prognostic score. European Archives of Oto-Rhino-Laryngology, 277, 2341-2347. https://doi.org/10.1007/s00405-020-05945-5

Vilches, L. A. (2020). Head and neck cancers new etiological insights. In C. P. Wild, E. Weiderpass, & B. W. Stewart (Eds.), World cancer report: Cancer research for cancer prevention (pp. 310-322). International Agency for Research on Cancer.

Wakasaki, T., Yasumatsu, R., Masuda, M., Takeuchi, T., Manako, T., Matsuo, M., Jiromaru, R., Uchi, R., Komune, N., Noda, T., & Nakagawa, T. (2020). Prognostic biomarkers of salvage chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. Cancers (Basel), 12, 2299. https://doi.org/10.3390/cancers12082299

Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., Jiang, J., & Robert, C. (2017). Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. Journal of Clinical Oncology, 35, 785-792. https://doi.org/10.1200/JCO.2015.66.1389

Yasumatsu, R., Wakasaki, T., Hashimoto, K., Nakashima, K., Manako, T., Taura, M., Matsuo, M., & Nakagawa, T. (2019). Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer. Head and Neck, 41, 2610-2618. https://doi.org/10.1002/hed.25737